Mode
Text Size
Log in / Sign up
N/A Completed N=153 Treatment

Evaluation of the Use of EZCare/V1STA in the Management of Acute and Chronic Wounds

Source: ClinicalTrials.gov NCT00994162 ↗
Enrolled (actual)
153
Serious AEs
1.3%
Results posted
Sep 2022
Primary outcomePrimary: Number of Wounds Stratified by Wound Area for the Performance of EZCare/V1STA in Terms of Wound Progress Towards Closure in Wounds Deemed Suitable for Treatment With Negative Pressure Wound Therapy (NPWT) - Wound Area (Baseline Measurements) — 36; 2; 28; 1 Wounds

Summary

The aim of this evaluation is to assess the performance of the EZCare/V1STA products, in many different clinical environments, in order to gain a greater insight into the effects of this negative pressure wound therapy (NPWT) in a variety of wound types.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Wounds Stratified by Wound Area for the Performance of EZCare/V1STA in Terms of Wound Progress Towards Closure in Wounds Deemed Suitable for Treatment With Negative Pressure Wound Therapy (NPWT) - Wound Area (Baseline Measurements)
36; 2; 28; 1; 63; 18
PRIMARY
Number of Wounds Stratified by Change in Wound Area for the Performance of EZCare/V1STA in Terms of Wound Progress Towards Closure in Wounds Deemed Suitable for Treatment With Negative Pressure Wound Therapy (NPWT) - Wound Area (Follow-up Visits)
5; 1; 27; 1; 4; 0
PRIMARY
Number of Wounds Stratified by Wound Volume for the Performance of EZCare/V1STA in Terms of Wound Progress Towards Closure in Wounds Deemed Suitable for Treatment With NPWT - Wound Volume (Baseline Measurements)
42; 11; 51; 5; 30; 4
PRIMARY
Number of Wounds Stratified by Change in Wound Volume for the Performance of EZCare/V1STA in Terms of Wound Progress Towards Closure in Wounds Deemed Suitable for Treatment With NPWT - Wound Volume (Follow-up Visits)
9; 3; 27; 8; 6; 0
PRIMARY
Number of Wounds Stratified by Wound Depth for the Performance of EZCare/V1STA in Terms of Wound Progress Towards Closure in Wounds Deemed Suitable for Treatment With NPWT - Wound Depth (Baseline Measurements)
4; 4; 99; 16; 19; 0
PRIMARY
Number of Wounds Stratified by Improvement in Wound Depth for the Performance of EZCare/V1STA in Terms of Wound Progress Towards Closure in Wounds Deemed Suitable for Treatment With NPWT - Wound Depth (Follow-up Visits)
42.2; 70; 47.8; 38.8; 48.8; 29.1
SECONDARY
Number of Participants Stratified by General Performance Characteristics Assessed for EZCare/V1STA NPWT - Ease of Application and Removal Participant Questionnaire
64; 6; 56; 13; 3; 1
SECONDARY
Number of Wounds Stratified by General Performance Characteristics Assessed for EZCare/V1STA NPWT - Duration of Wear Time
2.8; 2.3; 2.9; 3.1; 2.7; 2.6
SECONDARY
Number of Dressing Changes Stratified by General Performance Characteristics Assessed for EZCare/V1STA NPWT - Time for Each Dressing Change
19.7; 14.2
SECONDARY
Number of Wounds Stratified by Pain Level for the Analysis of Wound Pain Over the Treatment Period
58; 4; 42; 11; 24; 5
SECONDARY
Number of Wounds Stratified by Level of Odor for Analysis Over the Treatment Period
80; 18; 35; 3; 10; 0

Eligibility Criteria

Inclusion Criteria

  • The patient must be at least 18 years of age
  • Males and females - provided they are not pregnant and if of reproductive age are using contraception
  • The patient must have an acute or chronic wound deemed suitable for treatment with NPWT
  • The patient is able to understand the evaluation and is willing to consent to the evaluation

Exclusion Criteria

  • Presence of necrotic tissue or >25% slough in the reference wound. Once debridement has taken place the patient may proceed to enter the evaluation.
  • Previously confirmed and untreated osteomyelitis.
  • Malignancy in the reference wound bed or margins of the wound.
  • Active bleeding in the reference wound. Once haemostasis has been achieved, the patient may proceed to enter the evaluation.
  • Exposure of blood vessels or organs at the base of the reference wound.
  • Presence of untreated infection in the reference wound. (Infected wounds being treated with systemic antibiotics are permitted)
  • Patients with a known history of poor compliance with medical treatment.
  • Patients who have participated in this evaluation previously and who healed or were withdrawn
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00994162). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search